Welcome to our dedicated page for Meiragtx Holdings Plc SEC filings (Ticker: MGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to find trial updates buried in MeiraGTx’s 200-page reports? Biotech filings pack dense clinical data, FDA correspondence and manufacturing details that can overwhelm even seasoned analysts.
Stock Titan’s platform turns that complexity into clarity. Our AI reads every MeiraGTx quarterly earnings report 10-Q filing, parses risk-factor changes in the MeiraGTx annual report 10-K simplified, and flags fresh disclosures in each MeiraGTx 8-K material events explained. Instead of paging through tables on AAV vector yields, you receive concise summaries, key financial ratios and cross-links to original sections for deeper review.
Need to track executive behaviour? Real-time alerts surface MeiraGTx Form 4 insider transactions so you spot buying or selling as it happens. Curious about governance? The latest MeiraGTx proxy statement executive compensation is annotated, showing equity grants alongside performance milestones.
- Clinical-stage insight: Identify which pipeline programs advanced phases—directly from 10-Q and 10-K language.
- Capital runway at a glance: AI highlights cash-burn trends and funding needs investors watch closely.
- Compliance events: Each MeiraGTx 8-K is paired with plain-English context—partnerships, FDA feedback or financing rounds.
- Insider confidence: Follow MeiraGTx insider trading Form 4 transactions without manual EDGAR searches.
Whether you Google “understanding MeiraGTx SEC documents with AI” or ask, “How did MeiraGTx perform last quarter?”, our page answers in one place. Explore every filing type—10-K, 10-Q, S-3, Form 4—updated the moment EDGAR posts, complete with MeiraGTx earnings report filing analysis. Complex gene-therapy disclosures, simplified.
MeiraGTx reported continued operating losses as it advances its gene-therapy pipeline and manufacturing business. For the six months ended June 30, 2025 the company recorded a $78.8 million net loss and used $80.8 million of cash from operations. Cash, cash equivalents and restricted cash totaled $34.4 million at June 30, 2025 and the balance sheet showed a $780.8 million accumulated deficit, leaving shareholders' equity at $3.0 million.
Strategically, MeiraGTx signed a March 9, 2025 collaboration with Hologen that contemplates a $200 million upfront payment and up to $230 million of additional funding; Hologen made a $6.0 million payment in June 2025 and an additional $17.0 million payment in the third quarter of 2025, and the parties expect the transaction to close in the third calendar quarter of 2025, subject to customary conditions. The company also retains a supply agreement and contingent payments tied to the prior asset sale to Johnson & Johnson (an initial $65.0 million upfront in 2023 and $60.0 million in milestones received in 2024, with up to $350.0 million of contingent consideration remaining). Management states available cash, receivables, the $17.0 million deposit received and anticipated remaining collaboration proceeds are expected to be sufficient to fund operations for at least the next twelve months.
MeiraGTx Holdings plc (MGTX) – Form 4 insider transaction
President & CEO Alexandria Forbes reported the sale of 47,500 ordinary shares of MGTX on 8 July 2025. The shares were disposed of at a weighted-average price of $7.97 per share (individual trade prices ranged from $7.73 to $8.15). The transaction was executed under a Rule 10b5-1 trading plan adopted 21 Aug 2024, indicating it was pre-scheduled and not the result of ad-hoc decision-making.
Following the sale, Forbes’ direct beneficial ownership stands at 1,361,483 ordinary shares. No derivative securities were involved in this filing, and no additional transactions were reported.
The gross proceeds of the reported sale, based on the disclosed weighted-average price, total roughly $379 thousand. Forbes continues to serve as both Director and President & CEO of MeiraGTx.
Form 144 filing overview for MeiraGTx Holdings plc (MGTX)
The notice discloses a proposed sale of 47,500 ordinary shares through Merrill Lynch, 200 Park Avenue, New York, NY 10166. The transaction is scheduled for approximately 08 July 2025 on the NASDAQ exchange.
- Aggregate market value: $378,575
- Total shares outstanding: 80,365,359
- Percentage of float affected: ≈0.06%
The shares were originally acquired via incentive compensation stock grants on 02 March 2018 (35,625 shares) and 07 June 2018 (11,875 shares). The filer reports no other share sales within the past three months.
Because the sale represents a small fraction of outstanding stock and stems from equity compensation, the filing is generally considered routine. Investors often monitor Form 144s to gauge insider sentiment; however, the scale here is unlikely to materially impact market dynamics.
SEC Form 4 for MeiraGTx Holdings plc (MGTX) discloses that Richard Giroux, the company’s Chief Financial & Operating Officer, gifted 5,000 ordinary shares on 06/30/2025 (transaction code G, price $0). After this transaction, Giroux still owns 877,494 shares directly and 90,152 shares indirectly (5,152 via spouse; 85,000 via Aigle Healthcare Partners III LLC). No derivative positions were added or reduced, and the filing was signed on 07/02/2025. The Rule 10b5-1 checkbox is not marked, indicating the gift was not executed under a preset trading plan. The transaction reduces Giroux’s direct stake by approximately 0.6%, leaving his overall ownership essentially unchanged. There is no indication of operational or financial impact on MeiraGTx arising from this personal transfer.
MeiraGTx (NASDAQ:MGTX) filed an 8-K Regulation FD disclosure announcing it has obtained all required UK foreign-direct-investment clearances for its previously announced transactions with Hologen Ltd., signed March 9 2025.
The clearance removes the final regulatory hurdle, allowing the deal—which management expects to close in July 2025—to proceed to funding and execution.
FAQ
What is the current stock price of Meiragtx Holdings Plc (MGTX)?
What is the market cap of Meiragtx Holdings Plc (MGTX)?
